Anders Krogh Lemminger

Dr. Anders Krogh Lemminger

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MFMatteo Fiorenza
Matteo Fiorenza
ALAnders Krogh Lemminger
Anders Krogh Lemminger
MMMathias Marker
Mathias Marker
KEKasper Eibye
Kasper Eibye
FIF. Marcello Iaia
F. Marcello Iaia
MHMorten Hostrup
Morten Hostrup
The purpose of the present study was to investigate whether exercise training‐induced adaptations in human skeletal muscle mitochondrial bioenergetics are magnified under thermal conditions resembling sustained intense contractile activity and whether training‐induced changes in mitochondrial oxidative phosphorylation (OXPHOS) efficiency influence exercise efficiency. Twenty healthy men performed 6 wk of high‐intensity exercise training [ i.e ., speed endurance training (SET; n = 10)], or maintained their usual lifestyle ( n = 10). Before and after the intervention, mitochondrial respiratory function was determined ex vivo in permeabilized muscle fibers under experimentally‐induced normothermia (35°C) and hyperthermia (40°C) mimicking in vivo muscle temperature at rest and during intense exercise, respectively. In addition, activity and content of muscle mitochondrial enzymes and proteins were quantified. Exercising muscle efficiency was determined in vivo by measurements of leg hemodynamics and blood parameters during one‐legged knee‐extensor exercise. SET enhanced maximal OXPHOS capacity and OXPHOS efficiency at 40°C, but not at 35°C, and attenuated hyperthermia‐induced decline in OXPHOS efficiency. Furthermore, SET increased expression of markers of mitochondrial content and up‐regulated content of MFN2, DRP1, and ANT1. Also, SET improved exercise efficiency and capacity. These findings indicate that muscle mitochondrial bioenergetics adapts to high‐intensity exercise training in a temperature‐dependent manner and that enhancements in mitochondrial OXPHOS efficiency may contribute to improving exercise performance.—Fiorenza, M., Lemminger, A. K., Marker, M., Eibye, K., Iaia, F. M., Bangsbo, J., Hostrup, M. High‐intensity exercise training enhances mitochondrial oxidative phosphorylation efficiency in a temperature‐dependent manner in human skeletal muscle: implications for exercise performance. FASEB J. 33, 8976–8989 (2019). www.fasebj.org

20 January 2020 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
MHMorten Hostrup
Morten Hostrup
GJGlenn A. Jacobson
Glenn A. Jacobson
SJSøren Jessen
Søren Jessen
ALAnders Krogh Lemminger
Anders Krogh Lemminger

19 May 2018 in Scandinavian Journal of Medicine & Science in Sports
Verified
Journal Article
Closed access
PDF file
SJSøren Jessen
Søren Jessen
JOJohan Onslev
Johan Onslev
ALAnders Krogh Lemminger
Anders Krogh Lemminger
VBVibeke Backer
Vibeke Backer
JBJens Bangsbo
Jens Bangsbo
MHMorten Hostrup
Morten Hostrup

23 August 2019 in Scandinavian Journal of Medicine & Science in Sports
Verified
Journal Article
Closed access
PDF file
ALAnders Krogh Lemminger
Anders Krogh Lemminger
SJSøren Jessen
Søren Jessen
SHSajad Habib
Sajad Habib
JOJohan Onslev
Johan Onslev
SXStella Feng Sheng Xu
Stella Feng Sheng Xu
MHMorten Hostrup
Morten Hostrup

30 April 2025 in European Journal of Endocrinology
Verified
Journal Article
Open access
BMBradley S. Miller
Bradley S. Miller
JBJoanne C Blair
Joanne C Blair
MRMichael Højby Rasmussen
Michael Højby Rasmussen
JFJan Frystyk
Jan Frystyk
ALAnders Krogh Lemminger
Anders Krogh Lemminger
RHReiko Horikawa
Reiko Horikawa
Objective: Somapacitan is a long-acting GH approved for once-weekly treatment of GH deficiency (GHD). This study aims to evaluate the efficacy and tolerability of somapacitan after 3 years of treatment and 2 years after switch from daily GH in children with GHD. Design: Randomized, multi-national, open-labelled, active-controlled parallel-group phase 3 trial, with a 52-week main phase and 3-year safety extension (NCT03811535). Methods: Treatment-naïve children with GHD were randomized (2:1) to continuous somapacitan (0.16 mg/kg/week; “soma/soma” group) or daily GH (Norditropin®; 0.034 mg/kg/day) followed by somapacitan (0.16 mg/kg/week; “switch” group). Results: Of 200 participants, 188 completed 3 years of treatment. Sustained growth was observed in both groups. At week 156, mean (SD) height velocity (HV) between weeks 104 and 156 was 7.4 (1.5) cm/year in the soma/soma group and 7.8 (1.4) cm/year in the switch group. At week 156, the soma/soma and switch groups had reached a mean (SD) height SD score (HSDS) of −0.95 (0.98) and −1.08 (0.93), respectively, and were approaching the mean mid-parental HSDS of −0.74 (for both groups). Mean total insulin-like growth factor I (IGF-I) SDS during year 3 was similar between groups and within normal range (−2.0 to +2.0). Bioactive IGF-I and bioactive IGF-I to IGF-I ratio were similar between groups. Somapacitan was well tolerated, with low proportions reporting injection-site reactions. Conclusions: Sustained efficacy and tolerability were observed for continuous somapacitan treatment for 3 years, and for 2 years after the switching from daily GH treatment. HSDS in both groups was approaching mean mid-parental HSDS. Clinical trial registration: NCT03811535

13 September 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
AJAnders Juul
Anders Juul
PBPhilippe Backeljauw
Philippe Backeljauw
MHMichael Højby
Michael Højby
JFJan Frystyk
Jan Frystyk
Masanobu KawaiMasanobu Kawai
Masanobu Kawai
RHReiko Horikawa
Reiko Horikawa
Context: Somapacitan, a once-weekly reversible albumin-binding growth hormone (GH) derivative, is evaluated in short children born small for gestational age (SGA). Objective: Evaluate efficacy, safety, tolerability as well as total and bioactive insulin-like growth factor I (IGF-I) response of once-weekly somapacitan compared to daily GH in children born SGA. Methods: REAL5 is a randomized, multicenter, open-label, controlled phase 2 study comprising a 26-week main phase, a 26-week extension, and an ongoing 4-year safety extension (NCT03878446), conducted at 38 sites across 12 countries. A total of 62 GH-treatment-naïve, prepubertal short children born SGA were randomized; 61 completed 52-weeks of treatment. Patients were randomized (1:1:1:1:1) to somapacitan (0.16, 0.20, or 0.24 mg/kg/week) or daily GH (0.035 or 0.067 mg/kg/day), all administered subcutaneously. Results: Estimated mean height velocity (HV; cm/year) at week 52 was 8.5, 10.4, and 10.7 cm/year for somapacitan 0.16, 0.20, and 0.24 mg/kg/week, respectively, and 9.3 and 11.2 cm/year for daily GH 0.035 and 0.067 mg/kg/day, respectively. Dose-dependent increases in total IGF-I, as well as peak IGF-I bioactivity, were observed for both treatments and were similar between comparator groups. For somapacitan, exposure-response modeling indicated highest efficacy with 0.24 mg/kg/week after 52 weeks of treatment. Similar safety and tolerability were demonstrated across all groups. Conclusion: A sustained dose-dependent growth response was demonstrated for somapacitan after 52 weeks of treatment. Overall, somapacitan 0.24 mg/kg/week provides similar efficacy, safety, and tolerability, as well as comparable bioactive and total IGF-I response, as daily GH (0.067 mg/kg/day) in children born SGA.